198 related articles for article (PubMed ID: 26745042)
1. Benefits of Metformin Use for Cholangiocarcinoma.
Kaewpitoon SJ; Loyd RA; Rujirakul R; Panpimanmas S; Matrakool L; Tongtawee T; Kootanavanichpong N; Kompor P; Chavengkun W; Kujapun J; Norkaew J; Ponphimai S; Padchasuwan N; Pholsripradit P; Eksanti T; Phatisena T; Kaewpitoon N
Asian Pac J Cancer Prev; 2015; 16(18):8079-83. PubMed ID: 26745042
[TBL] [Abstract][Full Text] [Related]
2. Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma.
Jiang X; Ma N; Wang D; Li F; He R; Li D; Zhao R; Zhou Q; Wang Y; Zhang F; Wan M; Kang P; Gao X; Cui Y
Oncotarget; 2015 Feb; 6(5):3178-94. PubMed ID: 25605008
[TBL] [Abstract][Full Text] [Related]
3. Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines.
Ling S; Feng T; Ke Q; Fan N; Li L; Li Z; Dong C; Wang C; Xu F; Li Y; Wang L
Oncol Rep; 2014 Jun; 31(6):2611-8. PubMed ID: 24788596
[TBL] [Abstract][Full Text] [Related]
4. Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
Ling S; Xie H; Yang F; Shan Q; Dai H; Zhuo J; Wei X; Song P; Zhou L; Xu X; Zheng S
J Hematol Oncol; 2017 Feb; 10(1):59. PubMed ID: 28241849
[TBL] [Abstract][Full Text] [Related]
5. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
6. Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway.
Wandee J; Prawan A; Senggunprai L; Kongpetch S; Tusskorn O; Kukongviriyapan V
Life Sci; 2018 Aug; 207():172-183. PubMed ID: 29847773
[TBL] [Abstract][Full Text] [Related]
7. Impact of metformin on the incidence of human cholangiocarcinoma in diabetic patients: a systematic review and meta-analysis.
Laffusa A; Ciaccio A; Elvevi A; Gallo C; Ratti L; Invernizzi P; Massironi S
Eur J Gastroenterol Hepatol; 2023 Mar; 35(3):241-247. PubMed ID: 36708293
[TBL] [Abstract][Full Text] [Related]
8. Potential targeted therapy for liver fluke associated cholangiocarcinoma.
Vaeteewoottacharn K; Seubwai W; Bhudhisawasdi V; Okada S; Wongkham S
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):362-70. PubMed ID: 24408866
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylases and their inhibitors as potential therapeutic drugs for cholangiocarcinoma - cell line findings.
Sriraksa R; Limpaiboon T
Asian Pac J Cancer Prev; 2013; 14(4):2503-8. PubMed ID: 23725164
[TBL] [Abstract][Full Text] [Related]
10. MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.
Cheng CT; Chen YY; Wu RC; Tsai CY; Chiang KC; Yeh TS; Chen MH; Yeh CN
Oncol Rep; 2018 Sep; 40(3):1411-1421. PubMed ID: 30015968
[TBL] [Abstract][Full Text] [Related]
11. Metformin Exerts Antiproliferative and Anti-metastatic Effects Against Cholangiocarcinoma Cells by Targeting STAT3 and NF-ĸB.
Saengboonmee C; Seubwai W; Cha'on U; Sawanyawisuth K; Wongkham S; Wongkham C
Anticancer Res; 2017 Jan; 37(1):115-123. PubMed ID: 28011481
[TBL] [Abstract][Full Text] [Related]
12. Hydroxytyrosol inhibits cholangiocarcinoma tumor growth: an in vivo and in vitro study.
Li S; Han Z; Ma Y; Song R; Pei T; Zheng T; Wang J; Xu D; Fang X; Jiang H; Liu L
Oncol Rep; 2014 Jan; 31(1):145-52. PubMed ID: 24247752
[TBL] [Abstract][Full Text] [Related]
13. Diethyldithiocarbamate suppresses an NF-kappaB dependent metastatic pathway in cholangiocarcinoma cells.
Srikoon P; Kariya R; Kudo E; Goto H; Vaeteewoottacharn K; Taura M; Wongkham S; Okada S
Asian Pac J Cancer Prev; 2013; 14(7):4441-6. PubMed ID: 23992017
[TBL] [Abstract][Full Text] [Related]
14. Luteolin arrests cell cycling, induces apoptosis and inhibits the JAK/STAT3 pathway in human cholangiocarcinoma cells.
Aneknan P; Kukongviriyapan V; Prawan A; Kongpetch S; Sripa B; Senggunprai L
Asian Pac J Cancer Prev; 2014; 15(12):5071-6. PubMed ID: 24998588
[TBL] [Abstract][Full Text] [Related]
15. Methionine aminopeptidase 2 over-expressed in cholangiocarcinoma: potential for drug target.
Sawanyawisuth K; Wongkham C; Pairojkul C; Saeseow OT; Riggins GJ; Araki N; Wongkham S
Acta Oncol; 2007; 46(3):378-85. PubMed ID: 17450475
[TBL] [Abstract][Full Text] [Related]
16. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines.
Tepsiri N; Chaturat L; Sripa B; Namwat W; Wongkham S; Bhudhisawasdi V; Tassaneeyakul W
World J Gastroenterol; 2005 May; 11(18):2748-53. PubMed ID: 15884115
[TBL] [Abstract][Full Text] [Related]
17. The anticancer effects of Resina Draconis extract on cholangiocarcinoma.
Wen F; Zhao X; Zhao Y; Lu Z; Guo Q
Tumour Biol; 2016 Nov; 37(11):15203-15210. PubMed ID: 27683055
[TBL] [Abstract][Full Text] [Related]
18. 22-oxa-1,25-dihydroxyvitamin D3 efficiently inhibits tumor growth in inoculated mice and primary histoculture of cholangiocarcinoma.
Seubwai W; Wongkham C; Puapairoj A; Okada S; Wongkham S
Cancer; 2010 Dec; 116(23):5535-43. PubMed ID: 20681031
[TBL] [Abstract][Full Text] [Related]
19. Significance of S100P as a biomarker in diagnosis, prognosis and therapy of opisthorchiasis-associated cholangiocarcinoma.
Wu Z; Boonmars T; Nagano I; Boonjaraspinyo S; Srinontong P; Ratasuwan P; Narong K; Nielsen PS; Maekawa Y
Int J Cancer; 2016 Jan; 138(2):396-408. PubMed ID: 26312563
[TBL] [Abstract][Full Text] [Related]
20. Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients.
Casadei-Gardini A; Filippi R; Rimini M; Rapposelli IG; Fornaro L; Silvestris N; Aldrighetti L; Aimar G; Rovesti G; Bartolini G; Vivaldi C; Brunetti O; Sperti E; La Face R; Ratti F; Andrikou K; Valgiusti M; Bernardini L; Argentiero A; Fenocchio E; Frassineti GL; Cesario S; Giovannelli F; Quarà V; Leone F; Cascinu S
Oncology; 2021; 99(5):292-299. PubMed ID: 33626532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
